港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

維立志博-B

89.550

-4.300-4.58%

成交量：44.58萬

成交額：4,036.90萬

市值：178.20億

市盈率：-64.53

高：96.550

開：94.100

低：88.900

收：93.850

52周最高：97.500

52周最低：44.720

股本：1.99億

香港流通股本：1.53億

量比：1.40

換手率：0.29%

股息：- -

股息率：- -

每股收益(LYR):-1.388

淨資產收益率：-27.61%

總資產收益率：-9.92%

市淨率：12.27

市盈率(LYR):-64.53

市銷率: 87.66

資料載入中...

總覽公司新聞資訊公告

ASH伴髓外病變ORR 100%，維立志博LBL-034或改寫多發性骨髓瘤治療格局

維立志博－Ｂ(09887)出現大手賣出16.5萬股，成交價$47.25，涉資779.625萬

阿斯达克财经

維立志博-B(09887)：LBL-034臨床數據於第67屆ASH年會發布

每日沽空追蹤 | 維立志博-B 12月04日沽空量成交4.02萬股，沽空比例為7.2%

維立志博－Ｂ(09887)股價下跌5.323%，現價港幣$49.8

阿斯达克财经

已達成超10億美元合作，維立志博自免1類新藥在中國獲批臨床

維立志博-B(09887)：LBL-047取得NMPA的IND批准

每日沽空追蹤 | 維立志博-B 12月01日沽空量成交3.08萬股，沽空比例為6.56%

南京維立志博(9887)臨時股東大會將審議H股獎勵計劃等議案

速遞丨已達成超10億美元合作，維立志博自免1類新藥在中國獲批臨床

每日沽空追蹤 | 維立志博-B 11月26日沽空量成交4900股，沽空比例為1.4%

維立志博-B盤中異動早盤股價大漲5.39%

維立志博-B(09887)建議採納H股獎勵計劃

2025中國TCE賽道全景：百餘管線競逐，誰將領跑免疫治療新紀元？

ITBEAR科技资讯

每日沽空追蹤 | 維立志博-B 11月24日沽空量成交2.5萬股，沽空比例為2.33%

創新藥雙周報：4-1BB：覆盤歷史失敗原因維立志博做對了什麼？

每日沽空追蹤 | 維立志博-B 11月20日沽空量成交1.36萬股，沽空比例為4.3%

546 億融資背後的冷與熱：VC 們為何堅信創新藥是中國最好的投資行業？

先锋能源情报站

創新藥港股AB面

維立志博-B11月19日主力淨流出61.5萬元散户資金買入

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09887/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"維立志博-B","latestPrice":89.55,"timestamp":1776395041557,"preClose":93.85,"halted":0,"volume":445800,"delay":0,"changeRate":-0.045817794352690434,"floatShares":153000000,"shares":199000000,"eps":-1.387792399949897,"marketStatus":"交易中","change":-4.3,"latestTime":"04-17 11:04:27","open":94.1,"high":96.55,"low":88.9,"amount":40368995,"amplitude":0.081513,"askPrice":89.65,"askSize":3600,"bidPrice":89.4,"bidSize":1100,"shortable":3,"etf":0,"ttmEps":-1.3499435163148996,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1776398400000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":93.85,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"volumeRatio":1.398835,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.387792,"volumeRatio":1.398835,"shares":199000000,"dividePrice":0,"high":96.55,"amplitude":0.081513,"preClose":93.85,"low":88.9,"week52Low":44.72,"pbRate":"12.27","psRate":"87.66","week52High":97.5,"institutionHeld":0,"latestPrice":89.55,"committee":-0.531915,"eps":-1.387792399949897,"divideRate":0,"volume":445800,"delay":0,"ttmEps":-1.3499435163148996,"open":94.1,"prevYearClose":51,"prevWeekClose":92,"prevMonthClose":74,"prevQuarterClose":74,"fiveDayClose":92,"twentyDayClose":62.9,"sixtyDayClose":55.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762185600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-04-16","current":-69.533922,"percent":0,"low":-76.458084,"twenty":-42.63041,"median":-39.065878,"eighty":-33.470154,"high":-30.202688,"avg":-40.331276,"sd":9.254105,"marketCap":18540724450},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-16","current":-76.458084,"twenty":-42.63041,"median":-39.065878,"eighty":-33.470154,"marketCap":18540724450}],"updateTime":1776385892525},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590357391","title":"ASH伴髓外病變ORR 100%，維立志博LBL-034或改寫多發性骨髓瘤治療格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590357391","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590357391?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 14:54","pubTimestamp":1765176840,"startTime":"0","endTime":"0","summary":"TCE赛道产业爆发，应用边界不断延伸，技术持续迭代。在今年的ASH年会上，维立志博的条件性激活的GPRC5D/CD3双抗LBL-034，凭借颠覆多发性骨髓瘤治疗的潜力，入选ASH年会首场口头汇报的首个重磅议题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589802179","title":"維立志博－Ｂ(09887)出現大手賣出16.5萬股，成交價$47.25，涉資779.625萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802179","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802179?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 09:00","pubTimestamp":1765155600,"startTime":"0","endTime":"0","summary":"[大手成交]维立志博－Ｂ(09887)在上午09:00出现大手卖出，成交量为16.5万，成交价为港币$47.25，涉资779.625万。至目前为止，股价无升跌，今日最高价为$47.25，而最低价为$47.25，总成交量为16.5万股，总成交金额港币$779.625万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2512081/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2512081/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09887","BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589871029","title":"維立志博-B(09887)：LBL-034臨床數據於第67屆ASH年會發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2589871029","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589871029?lang=zh_tw&edition=fundamental","pubTime":"2025-12-07 18:28","pubTimestamp":1765103333,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2025年12月6日至9日，第67届ASH年会在美国佛罗里达州奥兰多召开。公司自主研发用于治疗复发性╱难治性多发性骨髓瘤的GPRC5D/CD3双特异性抗体LBL-034在大会首日第一个进行口头报告。LBL-034的主要临床亮点包括：LBL-034剂量递增至1,200μg/kg，未观察到任何剂量限制性毒性，未达到最大耐受剂量。与生活质量密切相关不良事件均为1至2级，多数不良事件发生于第一周期，在后续治疗中的发生率显著降低，不影响治疗连续性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK4109","LU2463526074.USD","09887","ASH","HK0000252160.HKD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2588838525","title":"每日沽空追蹤 | 維立志博-B 12月04日沽空量成交4.02萬股，沽空比例為7.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588838525","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588838525?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 16:30","pubTimestamp":1764837041,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月04日，跌0.94%，卖空量成交4.02万股，较上一交易日减少80.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163647978f8911&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163647978f8911&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588092639","title":"維立志博－Ｂ(09887)股價下跌5.323%，現價港幣$49.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2588092639","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588092639?lang=zh_tw&edition=fundamental","pubTime":"2025-12-03 13:04","pubTimestamp":1764738240,"startTime":"0","endTime":"0","summary":"[下跌股]维立志博－Ｂ(09887) 股价在下午01:04比前收市价下跌5.323%，现股价为港币$49.8。至目前为止，今日最高价为$53.4，而最低价为$49.8。总成交量为13.51万股，总成交金额为港币$691.501万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2512031845/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2512031845/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000252152.HKD","BK1161","HK0000500386.USD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588039756","title":"已達成超10億美元合作，維立志博自免1類新藥在中國獲批臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2588039756","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588039756?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 07:32","pubTimestamp":1764631937,"startTime":"0","endTime":"0","summary":"近日，中国国家药监局药品审评中心官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。值得一提的是，今年10月，维立志博宣布与Dianthus Therapeutics达成独家全球合作伙伴关系，共同推进LBL-047。维立志博将授予Dianthus在大中华区以外独家研发、生产及商业化LBL-047的权益，获得最高3800万美元的首付款及近期里程碑付款，其中包括2000万美元首付款、2025年第四季度支付的500万美元，以及最高1300万美元的潜在近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202091720a4c6c9a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202091720a4c6c9a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588382740","title":"維立志博-B(09887)：LBL-047取得NMPA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588382740","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588382740?lang=zh_tw&edition=fundamental","pubTime":"2025-12-01 16:32","pubTimestamp":1764577967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2025年11月25日，其自主研发候选药物LBL-047的新药临床试验申请已获中国国家药品监督管理局批准。目前全球范围内尚无同时靶向浆细胞样树突状细胞及B细胞的药物获批临床试验。LBL-047凭借此独特作用机制，具备同类第一及同类最优的潜力。其将评估LBL-047的安全性、耐受性及其在SLE患者中的初步临床有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","HK0000252160.HKD","IND","HK0000252152.HKD","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588471777","title":"每日沽空追蹤 | 維立志博-B 12月01日沽空量成交3.08萬股，沽空比例為6.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588471777","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588471777?lang=zh_tw&edition=fundamental","pubTime":"2025-12-01 16:30","pubTimestamp":1764577840,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月01日，跌0.94%，卖空量成交3.08万股，较上一交易日减少24.69%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163628a71c7317&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163628a71c7317&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196990754","title":"南京維立志博(9887)臨時股東大會將審議H股獎勵計劃等議案","url":"https://stock-news.laohu8.com/highlight/detail?id=1196990754","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196990754?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 22:17","pubTimestamp":1764339460,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技股份有限公司(股份代号：9887)将于2025年12月17日上午十时在中国南京市嘉陵江东街18号3幢8层召开临时股东大会，大会将以投票方式审议特别决议案，包括采纳H股奖励计划、授权董事会及/或代表办理相关事宜，以及就最多不超过已发行股份5%的新股配发申请上市。\n此外，还将表决服务供应商分项限额、取消监事会及修订公司章程等事项。更多详情可查阅香港联交所网站（www.hkexnews.hk）及公司网站（www.leadsbiolabs.com）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586214365","title":"速遞丨已達成超10億美元合作，維立志博自免1類新藥在中國獲批臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2586214365","media":"医药观澜","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586214365?lang=zh_tw&edition=fundamental","pubTime":"2025-11-27 11:41","pubTimestamp":1764214913,"startTime":"0","endTime":"0","summary":"中国国家药监局药品审评中心官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。值得一提的是，今年10月，维立志博宣布与Dianthus Therapeutics达成独家全球合作伙伴关系，共同推进LBL-047。维立志博将授予Dianthus在大中华区以外独家研发、生产及商业化LBL-047的权益，获得最高3800万美元的首付款及近期里程碑付款，其中包括2000万美元首付款、2025年第四季度支付的500万美元，以及最高1300万美元的潜在近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586252169","title":"每日沽空追蹤 | 維立志博-B 11月26日沽空量成交4900股，沽空比例為1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586252169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586252169?lang=zh_tw&edition=fundamental","pubTime":"2025-11-26 16:30","pubTimestamp":1764145838,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月26日，涨3.2%，卖空量成交4900股，较上一交易日减少93.61%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163622a71285c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163622a71285c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252160.HKD","09887","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586521872","title":"維立志博-B盤中異動 早盤股價大漲5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586521872","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586521872?lang=zh_tw&edition=fundamental","pubTime":"2025-11-26 11:00","pubTimestamp":1764126026,"startTime":"0","endTime":"0","summary":"2025年11月26日早盘11时00分，维立志博-B股票出现波动，股价快速上涨5.39%。截至发稿，该股报52.750港元/股，成交量12.81万股，换手率0.08%，振幅6.45%。维立志博-B股票所在的生物技术行业中，整体涨幅为2.43%。维立志博-B公司简介：我们是一家临床阶段生物科技公司,致力于创新疗法的发现、开发及商业化,以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126110026951ac4ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126110026951ac4ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252152.HKD","BK1161","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586712044","title":"維立志博-B(09887)建議採納H股獎勵計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2586712044","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586712044?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:48","pubTimestamp":1764082115,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2025年11月25日审议批准建议采纳H股奖励计划。H股奖励计划旨在：促进实现公司长远可持续发展及业绩目标;把受让人的利益与股东、投资者及公司的利益紧密联系起来，从而增强公司凝聚力，促进公司实现最大价值;及完善公司激励机制，以吸引、激励及留聘对公司持续经营、发展及长远增长贡献良多的集团董事、高级管理层及雇员。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586499055","title":"2025中國TCE賽道全景：百餘管線競逐，誰將領跑免疫治療新紀元？","url":"https://stock-news.laohu8.com/highlight/detail?id=2586499055","media":"ITBEAR科技资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586499055?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 18:06","pubTimestamp":1763978796,"startTime":"0","endTime":"0","summary":"与ADC依赖细胞毒素杀伤肿瘤细胞不同，TCE通过激活免疫系统实现治疗，对靶点表达量的要求较低，但对肿瘤特异性要求更高。在血液瘤领域，TCE已取得显著成果。截至2025年7月，全球已有9款TCE双抗获批上市，覆盖多发性骨髓瘤、弥漫大B淋巴瘤等多个适应症，市场规模超百亿美元。其CD19/BCMA/CD3三抗LBL-051通过NewCo模式与Aditum Bio合作，交易总额达6.14亿美元，创下国内临床前TCE管线授权纪录。平台型药企在TCE领域的优势日益凸显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124181626a70e196f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124181626a70e196f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02162","09887","BK1161","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586349287","title":"每日沽空追蹤 | 維立志博-B 11月24日沽空量成交2.5萬股，沽空比例為2.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586349287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586349287?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 16:30","pubTimestamp":1763973039,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月24日，跌0.49%，卖空量成交2.5万股，较上一交易日减少77.88%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124163606a70de1d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124163606a70de1d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585863834","title":"創新藥雙周報：4-1BB：覆盤歷史失敗原因 維立志博做對了什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2585863834","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585863834?lang=zh_tw&edition=fundamental","pubTime":"2025-11-23 00:00","pubTimestamp":1763827200,"startTime":"0","endTime":"0","summary":"目前有两款在研4-1BB双抗从设计上解决肝毒性，同时展现了惊艳的疗效，有望改写历史。MET-233i通过创新机制在Phase 1研究中单药即实现8.4%的安慰剂校正体重下降，且其约19天的半衰期为开发月度给药的固定剂量复方制剂奠定基础。这是全球首个 ADC 药物在食管癌治疗中取得 PFS/OS 双阳性结果的 III 期临床研究。创新药双周建议关注组合：康方生物、三生制药、映恩生物、信达生物、先声药业、歌礼制药、维立志博。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123172134a4b4c2d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123172134a4b4c2d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2399975544.HKD","LU2476274720.SGD","IE00BPRC5H50.USD","HK0000252152.HKD","BK1574","LU0417516738.SGD","BK1161","IE00B5MMRT66.SGD","LU0348784397.USD","LU0348766576.USD","LU1961090484.USD","LU1794554557.SGD","09926","LU2476274308.USD","LU0634319403.HKD","06978","LU2778985437.USD","LU0348767384.USD","LU0417516571.SGD","LU2488822045.USD","LU0348825331.USD","LU0348783233.USD","LU1720050803.USD","HK0000252160.HKD","LU0348735423.USD","HK0000500386.USD","09887","LU0540923850.HKD","LU0561508036.HKD","LU0348827113.USD","LU0417516902.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585682155","title":"每日沽空追蹤 | 維立志博-B 11月20日沽空量成交1.36萬股，沽空比例為4.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585682155","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585682155?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 16:30","pubTimestamp":1763627439,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月20日，跌0.47%，卖空量成交1.36万股，较上一交易日减少68%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120163804a706491d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120163804a706491d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585155662","title":"546 億融資背後的冷與熱：VC 們為何堅信創新藥是中國最好的投資行業？","url":"https://stock-news.laohu8.com/highlight/detail?id=2585155662","media":"先锋能源情报站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585155662?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 12:14","pubTimestamp":1763612098,"startTime":"0","endTime":"0","summary":"在资本市场的周期波动与行业调整中，中国创新药赛道正经历一场深刻的价值重塑。就在这样的行业节点，汉康资本、高瓴创投、晨兴创投、博远资本、汇鼎投资等头部 VC 集体发声，传递出清晰且坚定的信号：创新药仍是中国最好的投资行业之一，真正的机遇，正藏在这场结构性变革之中。汇鼎投资则紧扣老龄化趋势，布局退行性疾病、免疫与精准治疗三大赛道，坚持\"全球新\" 的投资标准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120140902a4ae7f90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120140902a4ae7f90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585651155","title":"創新藥港股AB面","url":"https://stock-news.laohu8.com/highlight/detail?id=2585651155","media":"深蓝观","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585651155?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 07:14","pubTimestamp":1763594040,"startTime":"0","endTime":"0","summary":"在2025年1月份的JP摩根医疗健康大会上，正好是中国创新药资产被全世界看见的时刻，会场上放眼望去，目之所及都是中国面孔。不过短短几个月，二级市场IPO开闸，3月份国际资金回流中国股市，港股IPO张灯结彩，2月份，一些即将上市的biotech又面临基石投资难求的困境，2个月后，基石又被疯抢。-02-繁华下的异动前几年被国内商业化、外资撤出等因素压下来的创新药的繁荣，2025年下半年，在港股打开一扇门后，被压抑的火苗，熊熊燃烧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120075224950f62e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120075224950f62e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887","09606","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584978543","title":"維立志博-B11月19日主力淨流出61.5萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2584978543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584978543?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 16:16","pubTimestamp":1763540164,"startTime":"0","endTime":"0","summary":"11月19日, 维立志博-B股价跌2.29%，报收53.35元，成交金额2827.6万元，换手率0.35%，振幅6.04%，量比1.08。维立志博-B今日主力资金净流出61.5万元，上一交易日主力净流入50.1万元。该股近5个交易日下跌7.06%，主力资金累计净流出109.6万元；近20日主力资金累计净流入634.2万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119162300a4ac4951&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119162300a4ac4951&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":158,"code":"91000000","status":"200"}]}}